What is the recommended dosing regimen for pembrolizumab, albumin‑bound paclitaxel (nab‑paclitaxel), and carboplatin in patients with squamous non‑small cell lung cancer?

Dosing Protocol for Pembrolizumab, Nab-Paclitaxel, and Carboplatin in Squamous NSCLC

For first-line treatment of metastatic squamous non-small cell lung cancer, administer pembrolizumab 200 mg IV on day 1, carboplatin AUC 5-6 IV on day 1, and nab-paclitaxel 100 mg/m² IV on days 1,8, and 15 of each 21-day cycle for 4 cycles, followed by pembrolizumab 200 mg IV every 3 weeks as maintenance therapy for up to 35 cycles (approximately 2 years). 1

Induction Phase (Cycles 1-4)

Each 21-day cycle consists of:

• Pembrolizumab: 200 mg IV on day 1
• Carboplatin: AUC 5-6 mg/mL/min IV on day 1
• Nab-paclitaxel: 100 mg/m² IV on days 1,8, and 15

This regimen is administered for exactly 4 cycles 1, 2.

Maintenance Phase (After Cycle 4)

Continue pembrolizumab monotherapy:

• Pembrolizumab: 200 mg IV every 3 weeks (day 1 of each 21-day cycle)
• Duration: Up to 35 total cycles of pembrolizumab (approximately 2 years from initiation) 1, 2

Key Clinical Considerations

PD-L1 Status

This regimen demonstrates survival benefit regardless of PD-L1 expression level 1, 2. The KEYNOTE-407 trial showed consistent overall survival improvement across all PD-L1 subgroups, making PD-L1 testing not required for treatment selection with this combination 2.

Alternative Paclitaxel Dosing

While the FDA label mentions both paclitaxel and nab-paclitaxel options, the specific nab-paclitaxel schedule of 100 mg/m² on days 1,8, and 15 was used in KEYNOTE-407 1, 2. Standard paclitaxel (175-200 mg/m² on day 1 only) is an alternative, but the question specifically asks about nab-paclitaxel.

Treatment Duration and Stopping Rules

• Continue pembrolizumab maintenance until disease progression per RECIST v1.1, unacceptable toxicity, or completion of 35 cycles 1
• Treatment beyond progression may be considered if the patient remains clinically stable and derives clinical benefit per investigator assessment 1
• Patients who complete all 35 cycles have excellent outcomes, with a 3-year OS rate of 69.5% after completion 3

Efficacy Outcomes

The 5-year data from KEYNOTE-407 demonstrates durable benefit:

• Median OS: 17.1 months with pembrolizumab combination vs 11.6 months with chemotherapy alone (HR 0.71) 3
• 5-year OS rate: 18.4% vs 9.7% 3
• Median PFS: 6.4 months vs 4.8 months (HR 0.56) 2

Safety Profile

• Grade ≥3 adverse events occur in approximately 70% of patients 2
• Treatment discontinuation due to adverse events: 13.3% 2
• Most common severe toxicities include neutropenia, anemia, and peripheral neuropathy
• Monitor for immune-related adverse events throughout treatment

Common Pitfalls to Avoid

1. Do not skip the days 8 and 15 nab-paclitaxel doses - this weekly dosing schedule is critical to the regimen's efficacy
2. Do not continue carboplatin beyond 4 cycles - only pembrolizumab continues as maintenance
3. Do not withhold treatment based on PD-L1 status - benefit is seen across all expression levels
4. Do not automatically stop at 2 years if responding - complete the full 35 cycles unless progression or toxicity occurs

This regimen represents a Category 1 recommendation from NCCN guidelines for first-line treatment of metastatic squamous NSCLC 4 and is FDA-approved based on the KEYNOTE-407 trial demonstrating superior overall survival and progression-free survival compared to chemotherapy alone 1.